Selected article for: "lung infection and macaque model"
Author: Tang, Qingquan; Li, Baojian; Woodle, Martin; Lu, Patrick Y.
Title: Application of siRNA Against SARS in the Rhesus Macaque Model
  • Cord-id: 16vgnq14
  • Document date: 2008_1_1
    • ID: 16vgnq14
    Snippet: Containment of the SARS coronavirus (SCV) outbreak was accompanied by the rapid characterization of this new pathogen's genome sequence in 2003, encouraging the development of anti-SCV therapeutics using short interfering RNA (siRNA) inhibitors. A pair of siRNA duplexes identified as potent SCV inhibitors in vitro was evaluated for in vivo efficacy and safety in a rhesus macaque SARS model using intranasal administration with clinical viable delivery carrier in three dosing regimens. Observation
    Document: Containment of the SARS coronavirus (SCV) outbreak was accompanied by the rapid characterization of this new pathogen's genome sequence in 2003, encouraging the development of anti-SCV therapeutics using short interfering RNA (siRNA) inhibitors. A pair of siRNA duplexes identified as potent SCV inhibitors in vitro was evaluated for in vivo efficacy and safety in a rhesus macaque SARS model using intranasal administration with clinical viable delivery carrier in three dosing regimens. Observations of SCV-induced SARS-like symptoms, measurements of SCV RNA presence in the respiratory tract, microscopic inspections of lung histopathology, and immunohistochemistry sections from 21 tested macaques consistently demonstrated siRNA-mediated anti-SCV activity. The prophylactic and therapeutic efficacies resulted in relief of animals from SCV infection-induced fever, diminished SCV in upper airway and lung alveoli, and milder acute diffuse alveoli damage (DAD). The dosages of siRNA used, 10 to 40 mg/kg, did not show any sign of siRNA-induced toxicity. These results support that a clinical investigation of this anti-SARS siRNA therapeutic agent is warranted. The study also illustrates the capability of siRNA to enable a massive reduction in development time for novel targeted therapeutic agents. We detail a representative example of large-mammal siRNA use.

    Search related documents:
    Co phrase search for related documents
    • acid dehydrogenase and acute respiratory syndrome: 1, 2, 3, 4
    • acid dehydrogenase and lower body temperature: 1
    • acute ards respiratory distress syndrome and low airway: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and lower number: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and low airway: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory syndrome and low appetite: 1, 2
    • acute respiratory syndrome and lower body temperature: 1
    • acute respiratory syndrome and lower number: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25